JP2020528885A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528885A5
JP2020528885A5 JP2020502320A JP2020502320A JP2020528885A5 JP 2020528885 A5 JP2020528885 A5 JP 2020528885A5 JP 2020502320 A JP2020502320 A JP 2020502320A JP 2020502320 A JP2020502320 A JP 2020502320A JP 2020528885 A5 JP2020528885 A5 JP 2020528885A5
Authority
JP
Japan
Prior art keywords
cells
cell
inhibitor
immune
hematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020502320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042822 external-priority patent/WO2019018603A2/en
Publication of JP2020528885A publication Critical patent/JP2020528885A/ja
Publication of JP2020528885A5 publication Critical patent/JP2020528885A5/ja
Priority to JP2024102476A priority Critical patent/JP2024123210A/ja
Pending legal-status Critical Current

Links

JP2020502320A 2017-07-19 2018-07-19 養子免疫療法における免疫細胞調節のための組成物および方法 Pending JP2020528885A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102476A JP2024123210A (ja) 2017-07-19 2024-06-26 養子免疫療法における免疫細胞調節のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762534537P 2017-07-19 2017-07-19
US62/534,537 2017-07-19
US201862628733P 2018-02-09 2018-02-09
US62/628,733 2018-02-09
PCT/US2018/042822 WO2019018603A2 (en) 2017-07-19 2018-07-19 COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102476A Division JP2024123210A (ja) 2017-07-19 2024-06-26 養子免疫療法における免疫細胞調節のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2020528885A JP2020528885A (ja) 2020-10-01
JP2020528885A5 true JP2020528885A5 (cg-RX-API-DMAC10.html) 2021-08-26

Family

ID=63104133

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502320A Pending JP2020528885A (ja) 2017-07-19 2018-07-19 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024102476A Pending JP2024123210A (ja) 2017-07-19 2024-06-26 養子免疫療法における免疫細胞調節のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102476A Pending JP2024123210A (ja) 2017-07-19 2024-06-26 養子免疫療法における免疫細胞調節のための組成物および方法

Country Status (4)

Country Link
US (1) US12036241B2 (cg-RX-API-DMAC10.html)
EP (1) EP3654986A2 (cg-RX-API-DMAC10.html)
JP (2) JP2020528885A (cg-RX-API-DMAC10.html)
WO (1) WO2019018603A2 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3914267A1 (en) 2018-01-25 2021-12-01 Mia Levite Methods for improved immunotherapy
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
WO2020092792A2 (en) * 2018-10-31 2020-05-07 Oncotracker, Inc. Method of enhancing immune-based therapy
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
AU2020254699A1 (en) * 2019-04-05 2021-12-02 2Seventy Bio, Inc. Manufacturing anti-BCMA CAR T cells
GB201909573D0 (en) * 2019-07-03 2019-08-14 Cancer Research Tech Ltd Modulation of T cell cytotoxicity and related therapy
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス,インコーポレイテッド 小化合物を使用するiPSC由来エフェクター免疫細胞の増強
FR3108501A1 (fr) * 2020-03-27 2021-10-01 Universite De Paris « Nouvelles cibles thérapeutiques à effet anti-inflammatoire et anti-interféron ».
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CN111454903B (zh) * 2020-05-06 2023-10-20 青岛瑞思德生物科技有限公司 免疫细胞体外培养、诱导、激活、冻存方法及其细胞库建立
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
WO2022120247A1 (en) * 2020-12-04 2022-06-09 Fate Therapeutics, Inc. Off-the-shelf ipsc-derived nk cell therapy for hematological cancer treatment
US20240150755A1 (en) * 2021-02-26 2024-05-09 Salk Institute For Biological Studies Modulating regulatory t cell function in autoimmune disease and cancer
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
CN116270588B (zh) * 2022-12-26 2025-07-25 中国科学技术大学 Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用
WO2024148402A1 (en) * 2023-01-12 2024-07-18 Peter Maccallum Cancer Institute A method of preparing cells for adoptive cell therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
CN119112823A (zh) * 2024-08-15 2024-12-13 吉林大学 一种仿生纳米复合材料及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
IL292504B2 (en) * 2015-10-20 2024-01-01 Kite Pharma Inc -methods of preparing t cells for t cell therapy
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies

Similar Documents

Publication Publication Date Title
JP2019502722A5 (cg-RX-API-DMAC10.html)
JP2019502725A5 (cg-RX-API-DMAC10.html)
US12036241B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US20240408200A1 (en) Methods of cell culture for adoptive cell therapy
Couture et al. HLA-class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy
JP2025038093A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
US11932870B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2022202172A1 (en) Improved methods of cell culture for adoptive cell therapy
Wrzesinski et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells
Liu et al. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
Robertson et al. Interleukin 12: basic biology and potential applications in cancer treatment
JP2020513243A5 (cg-RX-API-DMAC10.html)
JP7668781B2 (ja) 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
IL293564A (en) Enhancement of an effector immune cell, derived from an induced pluripotent stem cell, using small molecules
CA3123467A1 (en) Production and therapeutic use of off-the-shelf double negative t cells
CN118871572A (zh) 使用多种t细胞受体对干细胞t细胞进行工程化
Ritter et al. Effects of interleukin-12p40 gene transfer on rat corneal allograft survival
CN117979978A (zh) 从干细胞产生经工程化的t细胞
JP2024517966A (ja) 同種異系car t細胞療法のために幹細胞を操作すること
US20260071180A1 (en) Genetically engineered placental mucosalassociated invariant t (mait) cells and uses thereof
Liao et al. Mesenchymal stem cells and their immunomodulatory properties
HK40119436A (en) Genetically engineered placental mucosal-associated invariant t (mait) cells and uses thereof
Kawamoto et al. Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine
Cardoso Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?
Rotte et al. Promising immunotherapeutic approaches in clinical trials